KalVista Pharmaceuticals, Inc. (KALV) Announces Earnings Results
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its earnings results on Thursday. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08, Bloomberg Earnings reports. KalVista Pharmaceuticals had a negative return on equity of 63.41% and a negative net margin of 5,863.31%. The company had revenue of $0.10 million during the quarter.
Shares of KalVista Pharmaceuticals (NASDAQ KALV) traded down 0.12% on Friday, hitting $8.00. The stock had a trading volume of 2,385 shares. The company’s 50-day moving average price is $8.52 and its 200 day moving average price is $7.88. The firm’s market cap is $77.70 million. KalVista Pharmaceuticals has a 12-month low of $6.09 and a 12-month high of $10.65.
A number of equities research analysts have commented on KALV shares. ValuEngine raised KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd. BTIG Research started coverage on KalVista Pharmaceuticals in a research report on Thursday, August 31st. They issued a “buy” rating and a $18.00 price target for the company.
ILLEGAL ACTIVITY WARNING: “KalVista Pharmaceuticals, Inc. (KALV) Announces Earnings Results” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/15/kalvista-pharmaceuticals-inc-kalv-announces-earnings-results.html.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.